Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 7 Nov 2026
Promising but preliminary

Real-World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First-Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study.

BTK inhibitors cause more patients to stop treatment in real practice than clinical trials show, highlighting a need for better-tolerated first-line leukemia drugs.

This retrospective EHR-based cohort of 584 CLL/SLL patients in US community oncology found cBTKi discontinuation occurred more frequently than in clinical trials (51.2% at 24 months), driven primarily by adverse events, with ibrutinib associated with shorter time to discontinuation versus acalabrutinib. The majority of patients who discontinued first-line BTK inhibitor therapy did not receive subsequent treatment, highlighting unmet need for more tolerable 1L strategies in community practice.

What the study was

Study design
retrospective_cohort
Category
hematologic_malignancies
Maturity
Validated
Journal
eJHaem

Why it surfaced

Real-world community oncology data demonstrates substantially higher BTKi discontinuation rates than clinical trials; directly informs treatment selection and monitoring strategies for first-line CLL.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.